DRUG Bright Minds Biosciences Inc.

Bond yields have surged to levels last seen before the global financial crisis, which makes future cash flows harder to value and puts every growth story under a harsher spotlight. That pressure has not spared Canadian biotech shares, yet it also filters out weaker balance sheets and stretched valuations. This article highlights 3 Canadian biotechnology stocks from our quality focused screener that could merit a closer look today. The three stocks below are a small sample of what screens well...

Rising rates are squeezing indebted businesses. Meet three small cap stocks with strong revenue growth and low debt, plus a screener to find more like them.

Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.

The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).